P. Marinello

发表

Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study

Dinh Q. Phung, C. A. Shaw, M. Kumar, 2021, The Lancet Oncology.

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

D. Jäger, C. Atreya, E. Van Cutsem, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

S. Jagannath, S. Lonial, A. Oriol, 2019, The Lancet. Haematology.

Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.

N. Johnson, A. Santoro, P. Zinzani, 2021, The Lancet. Oncology.

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Shaji K. Kumar, F. Hernandez-Ilizaliturri, J. Pagel, 2021, Blood advances.

KEYNOTE-013 4-year follow-up of pembrolizumab in classical Hodgkin lymphoma after brentuximab vedotin failure.

P. Zinzani, P. Armand, J. Kuruvilla, 2020, Blood advances.

Pembrolizumab in relapsed or refractory Richter syndrome

A. Stathis, P. Armand, J. Pagel, 2020, British journal of haematology.

Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial

A. Lage, M. Catalá, R. Pérez, 2006, Cancer biology & therapy.

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2019, The Lancet. Haematology.

Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients

M. Taniwaki, S. Iida, J. Liao, 2021, International Journal of Hematology.

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

P. Gibbs, L. Diaz, E. Van Cutsem, 2020, The New England journal of medicine.

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

P. Borchmann, A. Engert, M. Fuchs, 2021, Leukemia.

Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients.

T. Crombet, L. E. Fernández, A. de la Torre, 2010, Human vaccines.

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

P. Gibbs, L. Diaz, C. Punt, 2022, The Lancet. Oncology.

KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.

L. Diaz, C. Atreya, Tae Won Kim, 2018 .

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study.

P. Gibbs, L. Diaz, Ping Yang, 2020, Journal of Clinical Oncology.

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

F. Prósper, I. Melero, B. Paiva, 2018, Haematologica.

Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

J. Miguel, N. Munshi, D. Reece, 2015 .

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

D. Siegel, N. Munshi, D. Reece, 2019, British journal of haematology.

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer.

P. Gibbs, Ping Yang, C. Punt, 2021 .

Pembrolizumab for myelodysplastic syndromes after failure of hypomethylating agents in the phase 1b KEYNOTE-013 study

G. Garcia-Manero, B. Smith, V. Ribrag, 2022, Leukemia & lymphoma.

KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

N. Johnson, A. Santoro, P. Zinzani, 2020, Journal of Clinical Oncology.

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

P. Zinzani, P. Armand, J. Palcza, 2019, Blood.

Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer

M. Amonkar, R. Aguiar-Ibáñez, N. Upadhyay, 2021, Journal of medical economics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study

P. Zinzani, N. Bartlett, J. Kuruvilla, 2022, Leukemia & lymphoma.

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013

D. Siegel, R. Vij, T. Wise-Draper, 2019, British journal of haematology.

Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study

P. Moreau, J. S. San Miguel, P. Marinello, 2021, British journal of haematology.

Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis.

D. Siegel, J. Miguel, N. Munshi, 2016 .

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

P. Gibbs, C. Punt, Tae Won Kim, 2021 .

Pembrolizumab monotherapy for patients with advanced MSI-H colorectal cancer: Longer-term follow-up of the phase II, KEYNOTE-164 study.

L. Diaz, Tae Won Kim, R. Guimbaud, 2020 .

Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL)

M. Shipp, N. Johnson, J. Radford, 2021, Blood.

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

M. Shipp, N. Johnson, J. Radford, 2018, Blood.

Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.

J. Miguel, N. Munshi, R. Mogg, 2017 .

Pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM): Randomized, phase 3 KEYNOTE-183 study

J. Shah, A. Palumbo, S. Jagannath, 2016 .

A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.

A. Lage, T. Crombet, G. Guillén, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164.

D. Jäger, E. Van Cutsem, R. Guimbaud, 2023, European journal of cancer.

Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies

D. Jäger, P. Ascierto, M. Maio, 2019, Annals of Oncology.

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, Journal of Clinical Oncology.

Favezelimab (anti–LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti–PD-1 treatment: An open-label phase 1/2 study.

N. Johnson, P. Zinzani, A. Bazargan, 2022, Journal of Clinical Oncology.

Induction of immune recognition of self-epidermal growth factor II: Characterization of the antibody response and the use of a fusion protein

A. Lage, G. Guillén, B. Sánchez, 1997 .

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Jason J. Z. Liao, S. Jagannath, S. Lonial, 2018 .

A phase 3 randomized study of pembrolizumab (Pembro) plus pomalidomide (Pom) and dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): KEYNOTE-183.

Jason J. Z. Liao, H. Goldschmidt, S. Jagannath, 2018 .

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer

P. Gibbs, C. Punt, Tae Won Kim, 2022, Cancer science.

P1086: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN ANTI–PD-1–NAIVE PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA: AN OPEN-LABEL PHASE 1/2 STUDY

N. Johnson, J. Kuruvilla, J. Timmerman, 2022, HemaSphere.

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma.

M. Shipp, N. Johnson, J. Radford, 2023, Blood.

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

J. Winter, A. Nahar, P. Marinello, 2021, Blood.

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

M. Shipp, B. Christian, J. Walewski, 2023, Blood.

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

M. Shipp, P. Zinzani, P. Armand, 2016 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients

Jason J. Z. Liao, H. Iwasaki, S. Iida, 2020, International Journal of Hematology.

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

M. Shipp, P. Zinzani, P. Armand, 2015 .

Real-World Treatment Patterns, Health Care Utilization, and Costs Among Relapsed/ Refractory Multiple Myeloma (rrMM) Patients

W. Zhou, M. Monberg, Y. Zhong, 2016 .

KEYNOTE-183: A randomized, open-label phase 3 study of pembrolizumab in combination with pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma (rrMM).

S. Jagannath, J. Miguel, A. Palumbo, 2016 .

KEYNOTE-185: a randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM).

A. Palumbo, S. Jagannath, J. Miguel, 2016 .